drugset / Trial / NCT02052362

Bioavailability of ABT-450 and ABT-267 With Ritonavir

NCT02052362

Phase 1 Completed 16 enrolled AbbVie
Non-randomizedParallel-groupOpen-label

Summary

A study to investigate the fraction of ABT-267 and ABT-450 absorbed by the body when given in combination with each other and Ritonavir(r).

Timeline

Start
2014-01
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject ombitasvir Small molecule
Subject paritaprevir Small molecule
Background Ritonavir Other / unclassified

Indications

No indication recorded.